Ann: LCT to sell JV Shares and receive DIABECELL licence, page-94

The Medical Advisors LCT utilise are based in NZ. The Data will be collated and sent to them to identify if any Significant Change.
Unlike Whytee, I do not think there is a swift remedy to any positive results, from my experience with Phase II and III companies cant dredge for results and Primary Endpoints after the Trial has concluded. I hope I am wrong and LCT can recover some time lost but i fear they will have to go the road of many other Bio-Techs and run the Trial again , this will take considerable time to redraw the Phase II parameters, initiate a trial patient search etc... LCT still have not been able to respond to not having a commercial model that will benefit Shareholders... It's still has its head in the sand being primarily a Research Team solely funded by Grants and CR's for 13 years.. even if management do discover something of benefit, do they have the ability to commercialise the Technology??? just sold $25m of value in a JV for $3m,,, had a MC of $140m now down to $16m..... with no revenue to date and no communication to the SH base or the wider Market, I would say they have all started to look for new positions...